Ablative Solutions Archives - Medical Design Sourcing

The top medtech trends of 2023

The top medtech trends of 2023 included innovations such as artificial intelligence, new GLP-1 weight loss drugs and some long-awaited medtech finally receiving regulatory nods.

With health providers facing additional challenges on top of an ever-uncertain economic environment, medtech companies also made major readjustments: layoffs, spinoffs, reorganizations and much more.

Here are the top stories that caught the attention of MassDevice readers and editors in 2023.

Top 2023 medtech trend No. 10: Questions about GLP-1 drugs

U.S. health providers wrote more than 9 million prescriptions in just three months for Wegovy, Ozempic and similar glucagon-like peptide-1 (GLP-1) weight loss drugs, according to analytics firm Trilliant Health. The popularity and initial effectiveness of the new drugs had medtech industry analysts asking a lot of questions about how the potential health benefits could reduce demand for devices. Medical device executives, however, we…

Ablative Solutions hits primary endpoint in renal denervation for hypertension trial

Ablative Solutions announced today that its TARGET BP I pivotal trial evaluating its Peregrine System kit met its primary endpoint.

The trial evaluates alcohol-mediated renal denervation to treat hypertension with the Peregrine System. Wakefield, Massachusetts-based Ablative Solutions reported a statistically significant difference in 24-hour ambulatory blood pressure between treatment and sham procedure at three months.

TARGET BP I evaluated the safety and efficacy of Peregrine to treat uncontrolled hypertension in patients taking anti-hypertensive medications. It evaluated 301 patients randomized to Peregrine treatment or sham procedure. The study remained blinded through six months follow-up.

The kit features a patented infusion catheter and dehydrated alcohol. Patients undergo a minimally invasive procedure to ablate the sympathetic nerves surrounding the renal arteries, reducing blood pressure.

Renal denervation has become a hot topic of late…

Ablative Solutions raises $91.4M in Series D financing round

Ablative Solutions today announced it completed the fourth tranche of its Series D financing round and raised $91.4 million.

Wakefield, Massachusetts-based Ablative Solutions earmarked the funds to complete the company’s ongoing Target BPI pivotal trial that is evaluating its alcohol-mediated renal denervation procedure.

Get the full story on our sister site, Medical Tubing + Extrusion.

Report: Medtech dollars, deals hit new highs in first half of 2021

Fueled at least in part by exceptionally strong IPO and M&A markets, hedge funds, venture capitalists, private equity firms and corporate investors are committing more time and money into privately held medical devices companies, according to a new “Healthcare Investments and Exits” report issued by Silicon Valley Bank.

The report examining the first half of 2021 outlines deals and dollars committed to all sectors within healthcare — while also tracking exiting opportunities for investors. An examination of the medical device portion of the report reveals many promising trends.

First, capital commitments are up. Looking at dollars raised, U.S. and European medical device startups raised $4.6 billion in the first half of this year, putting 2021 on pace to eclipse totals dollars raised in 2020 ($5.2 billion raised) and 2019 ($4.8 billion raised.) It’s worth noting that European startups accounted for 34% of the dollars raised by medical device companies, up f…